Despite the presence of well-known biomarkers such as VEGF, PARP, EGFR, and folate receptors that are targeted against by drugs that act as their inhibitors in ovarian cancer treatment, there are several obstructions that challenge the refinement for their clinical application using targeted therapies. Here, PARP1 is linked to ovarian carcinoma.